Conclusions
In addition to the recognized efficacy in RA, Crohn’s disease, and psoriatic arthritis, data on the therapeutic value of anti-TNF agents continues to accumulate in the treatment of a number of other autoimmune, inflammatory diseases. Could these agents become the corticosteroid of the 21st century?
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hassard, P.V., Binder, S.W., Nelson, V., et al., 2001, Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: a case report. Gastroenterology 120: 995–999.
Robertson, L.P., and Hickling, P., 2001, Treatment of recalcitrant orogenital ulceration of Behçet’s syndrome with infliximab. Rheumatology (Oxford) 40: 473–474.
Goossens, P.H., Verburg, R.J., and Breedveld, F.C., 2001, Remission of Behçet’s syndrome with tumour necrosis factor alpha blocking therapy. Ann. Rheum. Dis. 60:637.
Rozenbaum, M., Rosner, M., and Portnoy, E., 2002, Remission of Behçet’s syndrome with TNFalpha blocking treatment. Ann. Rheum. Dis. 61:283–284.
Sfikakis, P.P., Theodossiadis, P.G., Katsiari, C.G., et al., 2001, Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet 358:295–196.
Travis, S.P., Czajkowski, M., McGovern, D.P., et al., 2001, Treatment of intestinal Behçet’s syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49:725–728.
Munoz-Fernandez, S., Hidalgo, V., Fernandez-Melon, J., et al., 2001, Effect of infliximab on threatening panuveitis in Behcet’s disease. Lancet 358:1644.
Meliloglu, M., Fresko, I., Ozyazgan, Y., et al., 2002, Etanercept is beneficial in controlling the mucocutaneous manifestations of Behcet’s syndrome (BS) at short term but does not supress the pathergy reaction and the cutaneous response to intradermally injected monosodium urate crystals: A double blind, placebo controlled trial. Ann. Rheum. Dis. 61 suppl. I:37.
Bagnato, G., Arrigo, C., Bocchino, L., et al., 2002, Infliximab therapy for Behcet’s disease. Ann. Rheum. Dis. 61 suppl. I:216.
Erkan, D., Yazici, Y., Rusche, W., et al., 2002, Real-world experience with infliximab in the treatment of non-rheumatoid arthritis patients. Ann. Rheum. Dis. 61 suppl. I:465.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Calamia, K.T. (2004). Current and Future Use of Anti-TNF Agents in the Treatment of Autoimmune, Inflammatory Disorders. In: Zouboulis, C.C. (eds) Adamantiades-Behçet’s Disease. Advances in Experimental Medicine and Biology, vol 528. Springer, Boston, MA. https://doi.org/10.1007/0-306-48382-3_110
Download citation
DOI: https://doi.org/10.1007/0-306-48382-3_110
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-47757-7
Online ISBN: 978-0-306-48382-0
eBook Packages: Springer Book Archive